Given the pressing need to reduce the incidence of heart failure after MI, sgp130Fc warrants further investigation as a potential novel therapeutic in this setting.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE: The inflammatory cytokine IL-6 is associated with adverse outcomes after MI and is an emerging therapeutic target in coronary disease. Here, IL6 is linked to coronary artery disorder.